Avascular Necrosis, Congenital Hip Dysplasia, Osteoarthritis, Post-traumatic Arthritis, Rheumatoid Arthritis, Traumatic Femoral Fractures
Conditions
Keywords
Arthroplasty, Replacement, Hip, Conservative, Anatomic, Cementless
Brief summary
The purpose of this study is to monitor the performance of the DePuy PROXIMA™ hip in the treatment of patients with hip joint disease requiring a total hip replacement. Patients who enter the study will be evaluated at regular intervals following hip surgery using patient, clinical and x-ray assessments. A subset of patients will undergo scans to allow the bone mineral density of the bone surrounding the implant to be monitored
Interventions
DEVICEDePuy Proxima™ Hip
A short, anatomic, cementless femoral component for use in total hip arthroplasty
Sponsors
DePuy International
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
i) Male or female subjects between 18 and 70 years of age. ii) Subjects who are able to give voluntary, written informed consent to participate in this investigation and from whom consent has been obtained. iii) Subjects who, in the opinion of the Investigator, are able to understand this investigation, co-operate with the investigational procedures and agree to return to the hospital for all the required post-operative follow-ups. iv) Subjects who are scheduled to undergo a primary total hip replacement whom the surgeon considers to be suitable for the DePuy PROXIMA™ hip femoral prosthesis.
Exclusion criteria
i) Subjects who, in the opinion of the Investigator, have an existing condition/co-morbidity or infection that would compromise their long term participation and follow-up in this study. ii) Women who are pregnant. iii) Subjects who are known drug or alcohol abusers or with psychological disorders that could affect follow-up care or treatment outcomes. iv) Subjects who have participated in a clinical study with an investigational product in the last 6 month(s). v) Subjects who are currently involved in any injury litigation claims. vi) Subjects for whom the surgical procedure is a revision of a previous THR or hemi-arthroplasty, or who have previously undergone arthrodesis or osteotomy of the hip. vii) Subjects undergoing a simultaneous bilateral hip operation. viii) Subjects undergoing the second stage of a staged bilateral for whom the contralateral hip is part of this clinical investigation. ix) Subjects undergoing the second stage of a staged bilateral for whom the contralateral hip was implanted less than six months previously or is not performing satisfactorily
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Kaplan-Meier survivorship calculated at the five-year time-point | 5 yrs |
Secondary
| Measure | Time frame |
|---|---|
| Annual Kaplan-Meier survivorship calculations | Annually |
| Harris Hip Score | 6mths, 1yr, 2yrs, 5yrs, 7 yrs, 10yrs and 15 yrs post-surgery |
| Radiographic analysis | 6mths, 1yr, 2yrs, 5yrs, 7yrs, 10yrs and 15yrs post-surgery |
| Oxford Hip score | 6mths, and annually post-surgery |
Countries
Germany, Italy, Spain, United Kingdom
Outcome results
None listed